Pharvaris Outlook: Weak Technicals and Mixed Analyst Sentiment

Market Snapshot Headline Takeaway: Pharvaris (PHVS.O) is in a technically weak position with bearish indicators dominating and analysts showing mixed expectations. News Highlights Recent news has underscored volatility in the pharmaceutical sector. President Trump’s executive order on drug pricing is seen as a growing concern for the industry, potentially affecting Pharvaris if it faces pressure to reduce prices. Additionally,

regulatory changes under the HHS and FDA are adding uncertainty to product approvals and market access. While some firms received 510(k) clearance, others face delays or hurdles, which could impact overall market sentiment for the sector. Analyst Views & Fundamentals Analysts are split on Pharvaris, with three institutions offering a mix of “Buy” and “Strong Buy” ratings in the past 20 days. The simple average rating is 4.33, while the historical performance-weighted rating is 1.66, suggesting caution is warranted given past performance inconsistencies. Morgan Stanley (Matthew Joseph Harrigan) has a perfect 100.0% historical win rate. HC Wainwright & Co. (Patrick R. Trucchio) has a 0.0% historical win rate, casting doubt on its current “Strong Buy” rating. Wedbush (Laura Chico) has a 50.0% win rate and a “Buy” rating. This disparity in analyst ratings means the market is not aligned in its expectations. Meanwhile, the stock has seen a 0.63% price rise recently, which contrasts with the weighted pessimistic market expectations. On the fundamental side, key metrics are mixed: Price-to-Book (PB): 4.01 – High compared to peers (model score: 0/10) Price-to-Cash Flow (PCF): -13.72 – Weak cash flow metrics (model score: 0/10) Price-to-Sales (PS): 623.62 – Very high valuation relative to revenue (model score: 1/10) EV/EBIT: -10.57 – Weak profitability (model score: 0/10) Return on Assets (ROA): -0.38 – Below average efficiency (model score: 0/10) Gross Profit Margin (GPM): -0.19 – Subpar gross margin (model score: 2/10) Group Gross Margin (GMAR): -0.14 – Also weak (model score: 2/10) Money-Flow Trends Big-money investors and institutional flows are both negative, with 44.86% of total inflow still being recorded. However, the trend is downward across all categories, with extra-large and large investors showing 44.61% and 43.35% inflow ratios respectively, but still trending negatively. Retail investors are also cautious, with only 49.97% small inflow ratio and a negative trend. Key Technical Signals Technical indicators for Pharvaris paint a bearish picture. The technical score is 3.32 out of 10, with 4 bearish signals and 0 bullish in the last five days. Key indicators include: WR Overbought: internal diagnostic score 1/10 – historically weak with a -0.89% average return. RSI Overbought: internal diagnostic score 5/10 – mixed results but still bearish. Long Upper Shadow: internal diagnostic score 2/10 – weak reversal pattern. Bullish Harami Cross: internal diagnostic score 1/10 – a bearish trap according to historical performance. Key recent patterns include a Long Upper Shadow on 2025-11-20, and a Bullish Harami Cross on 2025-12-01, which is usually a bullish reversal but historically failed in this case. Technical indicators are suggesting weak momentum and an uncertain trend, with the market currently in a volatile state. Conclusion Pharvaris appears to be in a technically weak position with multiple bearish signals and mixed analyst ratings. Despite a recent price rise, the fundamentals and technicals do not support a bullish stance. Given the low internal diagnostic technical score of 3.32 and the bearish market flow, investors should consider waiting for a clearer breakout or a pullback before committing. Watch for any significant regulatory updates or earnings surprises, but for now, caution is warranted.